Levosimendan Kalceks (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which strengthens myocardial contraction without raising intracellular calcium concentrations. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and lowering after‑load, together enhancing overall cardiac output.

The dosing regimen for Levosimendan Kalceks is determined by the prescribing clinician based on the patient’s clinical status, weight, and hemodynamic response. The prescriber sets the infusion rate and duration according to approved guidelines and individual therapeutic goals.

Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be ruled out, the drug should be used only if the expected benefit justifies the potential hazard to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

The primary alternative inotrope is dobutamine, a beta‑adrenergic agonist that raises intracellular calcium to increase contractility. Levosimendan, by contrast, sensitizes troponin C to existing calcium and adds vasodilation, often resulting in less tachycardia and a more favorable myocardial oxygen balance, though both require careful monitoring.

Levosimendan Kalceks must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

The product is given as an intravenous infusion. After reconstitution according to the manufacturer’s instructions, the solution is administered through a controlled infusion pump, typically starting with a loading dose followed by a maintenance infusion, all under continuous hemodynamic monitoring.

The most serious adverse events include ventricular arrhythmias, severe hypotension, myocardial ischemia, and rare anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored continuously for cardiac rhythm and blood‑pressure changes during therapy.

Levosimendan is contraindicated in patients with severe hypotension (systolic pressure markedly low), uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in individuals with significant renal or hepatic impairment, where dose adjustment or alternative therapy may be required.